Valuation: Alzamend Neuro, Inc.

Market Cap 6.35M 5.64M 5.26M 4.8M 9.05M 610M 9.13M 63.68M 24.68M 312M 23.83M 23.31M 1B P/E 2027 *
-1.3x
P/E 2028 * -1.57x
Enterprise Value 6.35M 5.64M 5.26M 4.8M 9.05M 610M 9.13M 63.68M 24.68M 312M 23.83M 23.31M 1B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
97.34%
Yield 2027 *
-
Yield 2028 * -
1 day+4.18%
1 week-24.73%
Current month-20.81%
1 month-16.30%
3 months+22.32%
6 months+34.31%
Current year-24.73%
1 week 1.2
Extreme 1.2
1.92
1 month 1.2
Extreme 1.2
1.95
Current year 0.84
Extreme 0.84
2.54
1 year 0.84
Extreme 0.84
2.68
3 years 0.84
Extreme 0.84
318.6
5 years 0.84
Extreme 0.84
4,562.86
10 years 0.84
Extreme 0.84
45,292.48
Manager TitleAgeSince
Chief Executive Officer 50 19/11/2018
Director of Finance/CFO 64 04/08/2022
General Counsel 57 30/04/2019
Director TitleAgeSince
Chairman 56 25/02/2016
Chairman 57 31/05/2021
Director/Board Member 50 31/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26 Sell

Founder

-2,000 0.0417%
26/08/26 OtherCompany 0 0% -
31/07/26 FreeCompany 7,500 0.1565%
Change 5-day change 1-year change 3-year change Capi.($)
+4.18%-24.73%-44.08%-99.57% 6.35M
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-2.32%+23.28%+77.03% 59.26B
+0.89%-0.77%+5.80%+32.89% 47.14B
-0.96%-6.11%+26.70%+31.24% 42.91B
+0.36%+3.39%+350.59%+646.53% 44.13B
-0.20%-0.53%+6.84%+99.07% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+2.33%-8.58%-24.55%+340.08% 23.71B
Average +0.45%-3.35%+43.66%+129.14% 39.25B
Weighted average by Cap. +0.25%-0.40%+58.36%+145.81%

Financials

2027 *2028 *
Net sales - -
Net income -10.8M -9.6M -8.96M -8.16M -15.4M -1.04B -15.54M -108M -42M -531M -40.55M -39.67M -1.7B -10.8M -9.6M -8.96M -8.16M -15.4M -1.04B -15.54M -108M -42M -531M -40.55M -39.67M -1.7B
Net Debt - -
Logo Alzamend Neuro, Inc.
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Employees
5
Date Price Change Volume
02/10/26 US$1.370 +4.18% 236,382
01/10/26 US$1.315 -23.99% 150,749
30/09/26 US$1.730 -4.95% 21,693
29/09/26 US$1.820 +5.20% 49,609
28/09/26 US$1.730 -5.46% 83,827
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.315USD
Average target price
26.00USD
Spread / Average Target
+1,877.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALZN Stock